跳至主要内容
临床试验/NCT07800325
NCT07800325已完成不适用

The Safety and Efficacy of ECMO in the Management of Patients With Respiratory Failure

Life Shield Medical Technology Co., LTD1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2024年12月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
survival

研究概览

简要总结

Evaluation of the efficacy and safety of the Rengine extracorporeal cardiopulmonary support system and the ECMO sterile oxygenator in the management of respiratory failure.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18, male or female;
  • Patients with respiratory failure and high Paco2, PH < 7.35;
  • Researchers believe that this product is beneficial for patients undergoing treatment, such as patients with invasive ventilator weaning difficulty, large airway obstruction, etc;
  • Patients or guardians provided written informed consent voluntarily.

排除标准

  • Oxygenation index <80mmHg;
  • Intracranial hemorrhage or severe irreversible brain injury;
  • Thrombocytopenia;
  • Patients with malignant tumors (expected survival time <1 year);
  • patients unable to receive systemic anticoagulation;
  • Obesity: BMI>40kg/m2;
  • Those with a history of mental illness who were unable to cooperate in completing the trial;
  • During pregnancy and lactation;
  • Patients with allergic or severe allergic constitution to the test equipment;
  • Participated in other interventional device clinical trials within 3 months before this trial
  • Those who were deemed unsuitable to participate in the trial by the investigators.

研究组 & 干预措施

ECMO

Experimental

Using ECMO in the management of respiratory failure

干预措施: ECMO (Other)

结局指标

主要结局

survival

时间窗: Day 7 post-treatment

次要结局

未报告次要终点

研究者

发起方
Life Shield Medical Technology Co., LTD
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验